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Abstract 
In the last decades, the extension of life expectancy and the increased consumption of foods rich in saturated fats 
and added sugars have exposed the general population to emerging health problems. 
The prevalence of metabolic syndrome (MS), composed of a cluster of factors as obesity, dyslipidemia, 
hyperglycemia, and hypertension, is rapidly increasing in industrialized and developing countries leading to precocious 
onset of age-related diseases. Indeed, oxidative stress, accumulation of advanced glycation endproducts, and a chronic 
low-grade inflammation are common features of MS and physiological ageing. In particular, the entire set of MS factors 
contributes to the development of an inflammatory status named metaflammation, which has been associated with 
activation of early innate immune response through the assembling of the multiprotein complex inflammasome. The 
most investigated family of inflammasome platforms is the NOD-like receptor pyridine containing (NLRP) 3, which is 
activated by several exogenous and endogenous stimuli, leading to the sequential cleavage of caspase-1 and IL-1β, 
followed by secretion of active IL-1β. We here collect the most recent findings on NLRP3 activation in MS providing 
evidence of its central role in disease progression and organ dysfunction in target tissues of metaflammation, in 
particular in cardiovascular, hepatic and renal complications, with a focus on  oxidative stress and advanced glycation 
endproducts. A wide overview of the most promising strategies for the modulation of NLRP3 activation and related 
metabolic repercussions is also provided, since the finding of specific pharmacological tools is an urgent requirement to 
reduce the social and economic burden of MS- and elderly-associated diseases. 
 
Keywords: metabolic syndrome; metaflammation; NLRP3 inflammasome; oxidative stress; aging;  myocardial 
ischemia/reperfusion; steatohepatitis; chronic kidney disease. 
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1. INTRODUCTION 
In the last decades, two fundamental changes in the modern society have occurred: extension of lifespan and 
modification of eating habits. Even if improvements in public health care and advances in medical science have 
significantly extended life expectancy, on the other side the increased consumption of industrialized foods, high in 
saturated fats and added sugars, has exposed the general population to emerging health problems [1,2]. The onset of 
metabolic disturbances accompanying ageing, as obesity, metabolic syndrome (MS), and diabetes, has reached global 
epidemic proportions. Indeed, the World Health Organization has reported that worldwide 400 million adults are obese, 
about 6% of the general population. Particularly in the western countries the rate of obesity within the aging population 
is dramatically increasing: in the United States in the period between 2007 and 2010 about 8 million of adults aged 65-
74 were obese and it is expected that obese individuals will be at least the 75% of population by 2025 [3].  
Frequently, obesity is accompanied by a cluster of other factors, as dyslipidemia, hyperglycemia and 
hypertension, that taken together define the MS and increase the risk for the occurrence of diabetes and cardiovascular 
diseases (CVD), as well as hepatic and renal dysfunction [4-7].   
Indeed, many components of the MS, as obesity, hyperglycemia and hyperlipidemia, are individually associated to 
the establishment of a chronic low grade inflammation and oxidative stress that contribute to the development of the 
above-mentioned MS-related diseases [1,8]. Interestingly, a decline in innate immune response that generates a 
permanent inflammatory status and the accumulation of free radicals and glicoxidation and lipoperoxidation 
compounds, as advanced glycation endproducts (AGEs), are common features of the physiological ageing [9-12]. Thus, 
MS can be considered a condition that accelerates the natural mechanisms of ageing and lead to the precocious 
development of organ dysfunction [13]. 
This severely affects the social and economic burden of elderly-associated diseases, and MS should be considered 
as an important pathological process that requires to be specifically addressed. It is, therefore, mandatory to develop 
responsible strategies aimed at investigating and dissecting the mechanisms underlying MS in order to foresee 
therapeutic approaches.  
 
2. METABOLIC SYNDROME AND INFLAMMATION: METAFLAMMATION 
There is clearly increased risk of MS in obesity, which is also a major risk factor for a number of chronic diseases, 
including cancer, stroke, cardiovascular complications and premature death. In particular, there is strong evidence for 
the causative association between central (visceral) obesity and MS and the development of type 2 diabetes and 
cardiovascular complications, though the mechanisms are not fully understood [14]. Thus, the term metaflammation has 
been coined to define a low-grade, chronic inflammation orchestrated by metabolic cells in response to excess nutrients 
and energy in metabolic tissues including adipose, liver, muscle, pancreas, and brain [15]. 
The high level of coordination of inflammatory and metabolic pathways is highlighted by the overlapping biology 
and function of macrophages and adipocytes in obesity. Pre-adipocytes may exhibit anti-microbial and phagocytic 
properties and may differentiate into macrophages in the appropriate environment. Therefore, a potential immune role 
for pre-adipocytes has been suggested [16]. Furthermore, in obesity, macrophages and adipocytes co-localize in white 
adipose tissue. In this tissue, macrophages and/or adipocytes can contribute to the production of inflammatory 
mediators; thus macrophages may exert a potentially important influence in promoting insulin resistance. Besides 
macrophages, obesity is associated with aberrant expansion of other leukocytes (T cells, B cells, eosinophils, 
neutrophils, mast cells, and dendritic cells) in adipose tissue that contribute to chronic inflammation. In particular, the 
increased neutrophils lead to a rise of myeloperoxidase activity, a marker of neutrophil infiltration, in the damaged 
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tissue during inflammation [17]. Moreover, the recruitment of circulating dendritic cells through the release of 
adipokines from adipose tissue in response to systemic free fatty acids increase has been previously demonstrated [18]. 
Specifically, infiltrating dendritic cells in adipose tissue are activated by the interaction between HMGB1 bound to the 
DNA molecules and RAGE receptor on dendritic cells and thus participate in the initiation of metaflammation through 
the release of interferon-gamma [18].  
Despite the fact that specific inflammatory pathways that mediate the link between MS and the majority of 
chronic diseases have not yet been identified, most recent literature evidences suggest metaflammation to be a crucial 
link between the development of metabolic disorders and increased risk of CVD. In fact, visceral obesity and related 
insulin resistance increase cardiovascular risk by classical mechanisms such as dyslipidemia, hypertension and glucose 
dysmetabolism, and less conventional mechanisms, involving metaflammation [19]. Among less conventional risk 
factors there are adipokines, such as leptin and adiponectin, and proinflammatory cytokines, as interleukin(IL)-6 and 
tumor necrosis factor (TNF)-α, which are secreted by adipocytes and macrophages infiltrating adipose tissue that is 
considered an active endocrine organ. Altogether, these factors not only affect body weight homeostasis, but might lead 
to increased oxidative stress, endothelial dysfunction and vascular inflammation [20]. This process leading to monocyte 
recruitment, foam cell formation and subsequent development of fatty streaks, over many years, promotes 
atherosclerotic plaques, which, in the presence of enhanced inflammatory conditions, may become unstable and 
undergo to rupture; thus promoting occlusive thrombus formation [21]. 
 
3. THE NLRP3 INFLAMMASOME PLATFORM IN METABOLIC SYNDROME 
Before to start with considerations on MS and NOD-like receptor pyiridin domain containing (NLRP) 3, a brief 
general description of inflammasome, and in particular NLRP3 inflammasome, is necessary.  
The term inflammasome was proposed in 2002 by Martinon and collaborators to describe a high-molecular-
weight complex present in the cytosol of stimulated immune cells that determines the activation of inflammatory 
caspases [22]. Danger signals can be sensed by the cells through a group of pattern recognition receptors (PRRs) able to 
recognize structures conserved among microbial species, which are referred to as pathogen-associated molecular 
patterns (PAMPs), or as endogenous molecules released from damaged cells, called damage-associated molecular 
patterns (DAMPs). The PRRs are expressed not only in immune cells, particularly macrophages, but also in various 
non-immune cells. To date, four different classes of PRR families have been described. These families include 
transmembrane and cytoplasmic proteins. While the former includes C-type lectin receptors (CLRs) and the Toll-like 
receptors (TLRs), the latter comprise the Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and NOD-like 
receptors (NLRs) [23]. Among the NLRs, the best-characterized is the NLRP3 inflammasome (also known as NALP3 
and cryopyrin), which interacts with an apoptosis-associated speck-like protein including a caspase recruitment domain 
(ASC), thus recruiting and activating caspase-1. Since caspase-1 is an IL-1β-converting enzyme, it mediates the 
transformation of pro-IL-1β into mature IL-1β, which is released causing inflammation. Yet, the transcriptional 
induction of pro-IL-1β is required to have the induction of IL-1β release. Thus, a system including pro-IL-1β induction 
and inflammasome-mediated IL-1β maturation seems necessary for the regulation of this inflammatory cytokine [24].  
Most recent evidence has demonstrated the emerging role as a unifying cause of disease of the 
NLRP3inflammasome in DAMPs-induced ageing-related pathologies [25]. Inadequate inflammasome activity has been 
indeed involved in the pathogenesis of inflammatory diseases and metabolic disorders, and, interestingly, in ageing-
related diseases pathology-specific ligands (such as cholesterol crystals, oxidation-specific epitopes for atherosclerosis; 
Aβ for Alzheimer Disease; α-synuclein for Parkinson's disease; drusen, tiny clear accumulations of extracellular 
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material in the retinal pigment epithelium of the eye, for age-related macular degeneration and monosodium urate for 
gout) drive sterile inflammation through the activation of inflammasome [26-29].  
So far, no specific DAMPs have been identified linking ageing to MS, though we and others have recently 
contributed to demonstrate that NLRP3 inflammasome plays a pivotal role in the induction of insulin resistance and 
cardiac ischemia/reperfusion injury exacerbation [30-34]. Besides insulin resistance, it has also been proposed that 
NLRP3 “senses” obesity-associated danger signals and may contribute to obesity-induced inflammation [35].  
Given that MS is strictly related with increased risk for myocardial infarct and worse ischemia/reperfusion 
outcomes, we here review recent findings on the role of NLRP3 in different target organs of metabolic disturbances, 
with a focus on cardiac ischemia/reperfusion injury, hepatosteatosis, and diabetic nephropathy. 
 
3.1 NLPR3: mechanisms of activation 
The NLRP3 inflammasome is activated in response to a large number of stimuli, including the changes in intra-
cellular calcium levels, the production of reactive oxygen species (ROS) and the release of oxidized mitochondrial 
DNA, as well as in response to mitochondrial dysfunction, lysosomal destabilization, the formation of large nonspecific 
plasma-membrane pores and potassium efflux. 
However, the exact mechanisms of NLRP3 activation are not completely understood. It seems that NLRP3 is 
activated by a diverse range of agonists that differ both structurally and chemically with an unclear activation 
mechanism [36]. Actually, NLRP3 does not bind directly with any of its putative agonists/activators. In particular, no 
studies have yet demonstrated an interaction between the sensing domain of NLRP (LRR, leucine rich region) and any 
NLRP3 agonists. At moment, four different modalities of NLRP3 activation have been suggested: 1) mitochondrial 
ROS generation, 2) phagolysosomal destabilization, 3) potassium efflux, and 4) osmotic pressure and cell volume 
regulation.  
1) Several NLRP3 activators induce ROS formation from damaged mitochondria, which may activate the NLRP3 via 
an intermediate, such as the released mitochondrial DNA or the thioredoxin-interacting protein (TNXIP), which 
binds to NLRP3, thus obtaining its activation [37]. A recent study has proposed that ROS are necessary for 
priming the NLRP3 inflammasome, but not for its activation [38]. 
2) Large particulate matter, including alum, amyloid-β, and silica, may activate the inflammasome. Intracellular 
clogging of these particles leads to the formation and subsequent swelling of phagolysosome. Therefore, 
lysosomal matter, including cathepsin B is released and sensed by NLRP3 inflammasome, leading to its assembly 
[39]. 
3) Intracellular K+ efflux, obtained via the activation of purinergic receptor 7 (P2X7)-ATP-gated ion channels by 
extracellular ATP, results in NLRP3 inflammasome oligomerization. ATP-induced activation of P2X7 receptors 
has also been linked to pannexin-1 dependent formation of large nonselective cell membrane pores, which would 
allow NLRP3 activators to enter into the cells and to activate directly or indirectly NLRP3 [40,41].  
4) Finally, osmotic pressure and cell volume regulation have been associated to NLRP3 activation. It seems that 
hypotonic solution triggers a decrease in intracellular K+ and Cl- concentrations and a regulatory response leading 
to cellular volume decrease. This is due to the intervention of transient receptor potential (TRP) and transient 
receptor potential cation channel subfamily M member 7 (TRPM7), which mediate the intracellular Ca2+ handling. 
Both intracellular [Ca2+] variation and TRP channel-dependent volume decrease response may lead to the 
formation of caspase-1 [42]. This is in line with the finding that intracellular Ca2+ may activate the transforming 
growth factor β-activated kinase 1(TAK1) and that this enzyme plays a role in NLRP3 activation [43]. 
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Since a unified mechanism for NLRP3 activation lacks, it has been put forward the idea that different agonists 
may evoke similar downstream events that are sensed by NLRP3 [44]. Actually, the inflammasome products, IL-1β and 
IL-18, are targeted by many reagents, including the neutralizing IL-1β antibody canakinumab, the recombinant IL-1RA 
anakinra, the soluble decoy IL-1 receptor rilonacept, the IL-18–binding protein, the soluble IL-18 receptors and, indeed, 
the anti–IL-18 receptor monoclonal antibodies have been developed in the attempt to treat autoinflammatory diseases. 
However, only the evaluation of small molecules able to selectively inhibit the NLRP3 inflammasome can allow a 
better understanding of the role of the NLRP3 inflammasome-caspase-1-IL-1β/18 axis in the progression of specific 
diseases and may allow the future design of effective therapeutics. Notably, selective inhibition of NLRP3 by small 
molecules might have advantages compared with biological agents targeted at IL-1β and its receptor, including fewer 
immunosuppressive effects and better pharmacokinetics and cost-effectiveness. Unfortunately, so far, there has not been 
an effective development of inflammasome NLRP3 inhibitors. We recently tested, in vitro and in ex vivo model a small 
molecule as promising selective inhibition of NLRP3 [45].  
 
3.2 The ROS and AGEs as NLRP3 inducers in metabolic syndrome  
Clearly, the deterioration of the structure and function of organs during ageing is associated with oxidative stress, 
and disruption of homeostatic pathways. Lifelong exposure to different stressors results in a chronic oxidative stress 
process, leading to oxidative damage in biomolecules, a process thought to be a strong contributor to the process of 
ageing [46]. This oxidative situation leads to the release of DAMPs that initiate a sterile inflammation process [47].  
ROS may also result in the formation of AGEs, which are the product of the non-enzymatic reaction of reducing 
carbohydrates with lysine side chains and N-terminal amino groups of macromolecules (proteins, phospholipids and 
nucleic acids), that is the so-called Maillard reaction or glycation. Accumulation of AGEs has been evidenced in several 
target tissues of MS and as consequence of excessive intake of saturated fats and sugars [48-52]. Importantly, the 
progressive decline in mitochondrial efficiency during ageing is accompanied by increasing ROS levels and paralleled 
by accumulating AGEs in tissues [53]. In this context, a lifetime consumption of a high-AGEs-generating diet may 
evoke an acceleration of ageing processes [54]. AGEs, adversely affect the functional properties of proteins, lipids and 
DNA, and an association between augmented accumulation of AGEs and their receptor RAGE and an increased 
expression and activation of NLRP3 inflammasome has been hypothesized [55,56]. Actually, this association has been 
recently reported in pancreatic islets of obese and galectin-3, another receptor for AGEs, ablated animals. These effects 
were also associated with elevated phosphorylation of nuclear factor-κB (NF-κB), p65 and mature caspase-1 protein 
expression in both pancreatic and visceral adipose tissues [57]. Whether AGEs can activate NLRP3 directly acting as 
DAMPs or by the binding to AGEs-receptors remains to be ascertained. In particular, the complex redox-dependent 
pathway from AGEs to NLRP3 may include the inhibition of AMP-activated protein kinase (AMPK), thus exerting a 
control over mitochondrial metabolism, and therefore on inflammatory status of many cell types [58]. 
Understanding how AMPK-dependent pathways and the related pro-survival Reperfusion Injury Salvage Kinases 
(RISK) and Survivor Activating Factor Enhancement (SAFE) pathways regulate oxidative metabolism and substrate 
selection to control NLRP3 inflammasome-mediated inflammation holds promise for identifying new therapies for the 
treatment of MS dependent pathologies. Actually, in a recent article we have shown that diet-induced exacerbation of 
myocardial ischemia/reperfusion (I/R) injury evokes upregulation of NLRP3, which is associated to a downregulation 
of cardioprotective pathways, including RISK [33]. Further studies might clarify whether an inhibition of AGEs 
accumulation or AGEs-receptors signaling may restore protective pathways through the limitation of NLRP3 activation. 
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4. NLRP3 IN TARGET TISSUES OF METAFLAMMATION 
4.1. Heart: NLRP3 inflammasome in myocardial ischemia/reperfusion, an overview 
As previously mentioned, MS-related metaflammation boosts the risk of CVD and correlated comorbidities, such 
as type 2 diabetes. The correlation between MS and CVD is a much-extended field of research on cardiovascular 
pathology that is gaining more and more attention by scientists (with more than 75000 publications on this topic). In 
particular, MS and inflammation are linked to myocardial infarction and ischemic heart disease occurrence [59]. Here 
we will focus our discussion on the role of NLRP3 inflammasome in myocardial ischemia. 
In 2001 it has been observed for the first time that the secretion of IL-1β and IL-18 was increased in an I/R model 
of suprafused human atrial myocardium, thus providing a link between inflammasome activation and CVD 
development [60]. Since then on, the overexpression of the inflammasome complex has been detected in different 
models of myocardial I/R during the infarct process. This overexpression was observed in cardiac fibroblasts and 
infiltrating cells, but also in cardiomyocytes of the border zone of the infarction in post-ischemic myocardium [61,62].  
In conditions of MS and diabetes, TXNIP, which is typically upregulated by hyperglycemia, may mediate NLRP3 
inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial I/R injury [63].  
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Indeed, the block of TXNIP/NLRP3 signaling can inhibit the activation of NLRP3 inflammasomes and may be an 
interventive strategy to improve myocardial I/R outcome. 
It is likely that the formation of the NLRP3 inflammasome in the myocardium during acute heart ischemia may 
amplify the inflammatory response, thus mediating further injury. It seems that the signaling pathways regulating the 
inflammasome formation in the cardiac tissue require a priming signal (transcription of inflammasome components) to 
allow an active NLRP3 to mediate caspase-1 activation and LV dysfunction. Ischemia/reperfusion injury induces both a 
priming signal and a trigger (NLRP3 activation). Therefore, NLRP3 inflammasome may be active in the ischemic heart 
to favor caspase-1 activation, inflammation and cell death [64]. 
It seems that triggers for the NLRP3 inflammasome complex are similar to those responsible for myocardial I/R 
injury and perhaps to those involved in ischemic preconditioning (PreC). For these reasons, Zuurbier et al. [65] tested 
the hypothesis that NLRP3 inflammasome plays a role either in PreC or in acute I/R injury of the heart. To this aim they 
used Langendorff-perfused hearts from wild-type and NLRP3(-/-) mice. Surprisingly, the deletion did not affect I/R-
induced cell death, but exacerbated I/R-induced mechanical dysfunction, and abolished the protective effects of PreC 
against I/R injury. Since NLRP3(-/-) hearts had lower levels of IL-6 and lower signal transducer and activator of 
transcription  (STAT)3 expression after PreC, the authors suggested that the observed effects are due to an altered IL-
6/STAT3 dependent mechanism. 
Moreover, Hermansson et al. [66] studied how NLRP3 molecules are influenced in human ischemic cardiac 
tissue. Intriguingly, NLRP3 levels were markedly low in human ischemic myocardial tissue compared with non-
ischemic control cardiac tissue. However, gene analysis revealed mutations in NLRP3 in human heart tissues from 
ischemic subjects, but not in those from non-ischemic controls. The authors concluded that genetic defects in the 
inflammasome and associated proteins may represent a background for promoting ischemic cardiac disease. 
A little at variance with above studies, Sandanger et al. [67] found that hearts isolated from NLRP3(-/-) mice, 
displayed a marked improvement of mechanical function and reduced injury after an I/R protocol, when compared with 
the responses of wild-type hearts to I/R challenge. Moreover, NLRP3 inflammasome resulted up-regulated in 
myocardial fibroblasts of wild-type hearts few days after a permanent coronary occlusion. Thus, the authors suggested 
that the NLRP3 upregulation may be an important contributor to infarct size development during ischemia. 
Of note, both the study by Zuurbier et al. [65] and the study by Sandanger et al. [67] suggest important 
inflammasome-independent effects of myocardial NLRP3, as these two studies report a clear difference in phenotypes 
comparing NLRP3(-/-) and ASC(-/-) hearts. However, and surprisingly enough, the latter group of researchers [68] in a 
recent study observed a larger infarct size in NLRP3(-/-) and ASC(-/-) mice (no difference in the two KO mice), 
suggesting a cardioprotective role for the NLRP3 inflammasome in myocardial I/R injury, and these authors conclude: 
“Our data imply that NLRP3 contributes to cardio-protection during I/R and do not support a role for NLRP3 or ASC 
inhibition in the management of acute myocardial infarction including revascularization therapy”. Yet, as noted by 
Toldo et al. [34], these conclusions set forth by Sandanger et al. [68] are not completely supported by the data of the 
article, in which, for example, troponin I levels, used as marker of myocardial injury, at 24 h of reperfusion were similar 
in the treated and control groups.  In this line is also our recent report [33], in which we demonstrated that the heart of 
mice fed with a high-fat high-fructose diet for 12 weeks had a marked overexpression of both NLRP3 and markers of 
oxidative metabolism, and a downregulation of both the hypoxia inducible factor (HIF)-2α and the factors of the RISK 
pathway. When exposed to cardiac ex vivo I/R protocol these hearts displayed a greater infarct size and lactic 
dehydrogenase release in comparison with control mice. The majority of above reported studies display a role for 
NLRP3 activation in the exacerbation of myocardial I/R injury. However, the discrepancies in the above reported 
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investigations underscore the need for further studies to elucidate the role for NLRP3 inflammasome within the heart. 
Moreover, pharmacological studies are necessary to determine, among other things, mechanisms of action of the tested 
drugs and tissue and serum drug levels after local or systemic administration.  
 
4.2 Liver: NLRP3 inflammasome in steatohepatitis, an overview 
The typical hepatic outcome of MS and over-nutrition is the nonalcoholic fatty liver disease (NAFLD), where the 
increasing deposition of intracellular lipids may evolve in steatohepatitis (NASH) and fibrosis [69]. Several factors 
contribute to the progression from NAFLD to NASH, and the currently hypothesized mechanism is based on a “two-
hit” hypothesis. The first hit includes steatosis and insulin resistance, and these conditions seem to sensitizes the liver 
for later events leading to the development of steatohepatitis. The second hit is a multifactorial process including 
oxidative stress, lipid peroxidation, and mitochondrial dysfunction that concur to the chronic inflammatory response 
[70,71], as occurring in metaflammation. Around 10–20% patients with NAFLD will eventually develop NASH [71], 
which has been predicted to be the leading indication for liver transplantation in the USA by the year 2020 [72].  
Recent studies in murine models and in human patients with NASH reviewed by Wan and colleagues [73] have 
evidenced the increased expression of NLRP3 and demonstrated that genetic deletion or pharmacological inhibition of 
genes related to NLRP3 resulted in alleviation of hepatic steatosis, inflammation, and fibrosis, suggesting that NLRP3 
inflammasome may play a critical role in the development of NASH and may act as a molecular therapeutic target. 
However, the mechanisms linking MS-related hepatosteatosis to NLRP3 activation and further progression to NASH 
are not fully understood.  
In particular, the most likely factor triggering hepatic inflammation in MS is the lipotoxicity induced by the 
excessive flux of free fatty acids through hepatocytes [74] resulting in accumulation of saturated fatty acids, as 
palmitate, and sphingolipid metabolism intermediates as ceramide [74,75]. In fact, both palmitate and ceramide have 
been ascribed for NLRP3 inflammasome activation in in vitro and in vivo studies [35,75]. In a work by Sui et al. [76], a 
high fat diet was able to induce in mice hepatosteatosis and inflammasome activation, but when the diet was enriched 
by polyunsaturated fatty acids, the liver showed decreased sensitization to lipopolysaccharide (LPS)-induced NLRP3 
inflammasome activation. In particular, authors showed that palmitic acid was able to directly activate NLRP3 
inflammasome in cultured primary hepatocytes, while the polyunsaturated docosahexaenoic acid inhibited LPS-induced 
NLRP3 activation.  
In the development of steatohepatitis the resident macrophages are critical in maintaining tissue homeostasis, 
regulating lipid metabolism, energy homeostasis, and tissue remodeling. An elegant in vitro study on bone marrow–
derived macrophages revealed that ceramide exposition causes activation of caspase-1. Notably, both caspase-1 
activation and IL-1β secretion from macrophages induced by ceramide were blocked in the absence of Nlrp3 [35], 
suggesting that accumulation of ceramide may be a potent direct inducer of inflammasome activation also in hepatic 
macrophages.  
In MS, the accumulation of palmitate and ceramide is often reported as a typical result of an excessive de novo 
lipid synthesis due to a deregulated activation of the transcription factor sterol regulatory element-binding protein 
SREBP1c which regulate the transcription of the enzymes involved in lipogenesis [77,78]. In this contest, there is 
emerging evidence that AGEs deriving from high fats and sugars intake can interfere not only with SREBP activity, but 
also with sphingolipids metabolism leading to the specific accumulation of palmitate and ceramide, respectively 
[79,80]. Moreover, literature data indicate that SREBP itself can induce NLRP3 transcription in atherosclerotic plaques 
[81-83] and a reciprocal activation between SREBP and NLRP3 is reported in liver with hepatitis C infection [84]. 
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Indeed, the inhibition of TNXIP by quercetin and allopurinol leads to the concomitant downregulation of SREBP and 
NLRP3 activities in the liver of streptozotocin-induced diabetic rats [85]. Taken together, the above-mentioned findings 
confirm the tight relationship between an unbalanced lipid metabolism with NLRP3 inflammasome activation in the 
liver.  
A further interesting observation concerning the role of diet-derived AGEs in MS-related NLRP3 activation is that 
the AGEs receptors RAGE and galectin-3 seem to be involved in inflammasome modulation in macrophages. In 
particular RAGE is suggested to exert an indirect action on NLRP3 as it prepares its activation by promoting the 
transcription of pro-caspase-1 and pro-IL1β that are secreted in a second time [55]. Otherwise, the upregulated 
expressions of galectin-3 and NLRP3 were directly correlated in the liver of patients with primary biliary cholangitis 
and in a mouse model of autoimmune cholangitis, with subsequent activation of caspase-1 and IL-1β secretion. In the 
same study, the hepatic activation of NLRP3 was impaired and inflammation significantly reduced when galectin-3 was 
knocked out in the autoimmune cholangitis model [86]. In regards to MS, a previous interesting work demonstrated that 
the ablation of galectin-3 in mice put on a 60% fat diet leads to a worsening of lipids accumulation within hepatocytes 
compared to the wild type mice fed the same diet, but this enhanced steatosis was paralleled by improvement of the 
inflammatory profile with downregulated NLRP3 and IL-1β expression, and reduced fibrosis and cell damage [87]. 
Despite a substantial number of studies indicating the prominent role of macrophages in NLRP3-induced hepatic 
inflammation, an interesting study evidenced that NLRP3 activation in steatohepatitis can also occur in hepatocytes, in 
addition to immune cells [88]. Indeed, the selective deficiency of myeloid differentiation primary response 88 (MyD88) 
gene, one of the main transducers of DAMPs signaling leading to NLRP3 complex assembling, either on bone marrow-
derived or non-bone marrow-derived cells, downregulates NLRP3 expression, caspase-1 activation, and IL-1β 
production. However, an attenuation of liver injury was detected only when MyD88 was deleted in macrophages [88]. 
 
4.3 Kidney: NLRP3 inflammasome in diabetic nephropathy, an overview 
The finding that diabetic patients have high levels of IL-18 in plasma and urine which positively correlate with 
albumin excretion suggested an involvement of inflammasome in diabetic nephropathy [89]. An elegant study on an 
animal model of diabetic nephropathy showed that increased renal NLRP3 expression and IL-1β and IL-18 levels 
preceded albuminuria, mesangial cells expansion and glomerulosclerosis onset, that were prevented by NLRP3 
deficiency, independently from glucose control, confirming the direct causative role of inflammasome in nephropathy 
[90]. In the same study, it has been demonstrated through transplantation of NLRP3-deleted bone marrow cells in db/db 
mice or wild type bone marrow cells in NLRP3-deleted streptozotocin-diabetic mice, that the activation of NLRP3 
signaling in renal resident cells has a greater impact than that of infiltrating immune cells in early stages of nephropathy 
development [90]. In particular, recent literature data have evidenced that NLRP3 is expressed and potentially activated 
in kidney diseases in different renal resident cells, such as podocytes, glomerular endothelial cells, and tubular 
interstitial epithelial cells [90,91].  
It is widely demonstrated that besides the onset of hepatosteatosis and cardiovascular diseases, the MS confers 
also increased risk for chronic kidney disease (CKD) [92]. As so far evidenced, dyslipidemia is the MS-related factor 
mainly responsible for cardiovascular risk and hepatic inflammation, while the role of lipid metabolism in the onset of 
CKD is still under debate. However, almost all the elements above described for cardiac and hepatic outcomes of lipid 
metabolism disturbances have been shown to have a role in renal disease development. Indeed, lipotoxicity induced by 
intracellular lipid accumulation (including saturated fatty acids and ceramide), altered lipid synthesis due to SREBP 
over-activation, and lipid peroxidation inducing AGEs production, have been recognized as leading causes of 
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glomerulosclerosis and tubulo-interstitial damage in animal models of diabetes [93,94]. In this regard, a very recent 
study has demonstrated the beneficial effect of sphingomyelinase ablation that, by reducing the high-fat diet-induced 
ceramide production, prevents NLRP3 inflammasome complex formation and subsequent IL-1β production in 
podocytes, attenuating glomerular damage and proteinuria [95]. 
Thus, even in kidney the lipotoxicity-driven inflammation and fibrosis are underlying mechanisms of tissue 
damage [93] and the potential role of NLRP3 inflammasome in diet-induced metaflammation in kidney is currently 
intensively investigated.  
An interesting work comparing the effects of a western-style diet and high-fructose drinking in wild type and 
NLRP3 knockout mice demonstrated that the activation of NLRP3 signaling is fundamental for the renal macrophagic 
infiltration and profibrotic signal in diet-induced nephropathy. Moreover, the NLRP3 deletion significantly prevented 
renal lipids accumulation by downregulating SREBPs activation, confirming a tight relation between lipid synthesis and 
NLRP3. Furthermore, NLRP3 knockout mice had also strongly reduced hyperuricemia and albumin excretion, 
especially those fed the western-diet [96]. 
Hyperuricemia is an important aspect of MS associated to the progression of renal failure [97]. Indeed, uric acid 
has been demonstrated by in vitro studies to exert a pro-inflammatory action on endothelial and epithelial tubular cells 
promoting the release of HMGB1 that stimulates the TLR4 and the assembling of NLRP3 inflammasome platform in 
recruited macrophages [98,99]. Indeed, the reduction of circulating uric acid by allopurinol on high fat diet-induced 
hyperuricemia in a rat model of type 2 diabetes also led to attenuated renal infiltration of macrophages with activated 
NLRP3 and secreting IL-1β, and overall improved nephropathy, even in absence of glycemic control [99].    
However, in addition to lipotoxicity, another proposed mechanism for inflammasome activation in renal cells in 
diabetes and MS, is linked to hyperglycemia that through enhanced glycolytic flux in mitochondria promotes ROS, 
AGEs, and ROS-mediated TXNIP production, all potential activators of inflammasome platform [37,100,101]. In 
particular, the AGE-RAGE axis has been found to enhance the podocytes expression of NLRP3 and cleavage of IL-1β 
[100].  
Previous studies have found in the glomeruli of diabetic rats and in a model of inflammatory acute renal injury an 
up-regulation of the purinergic 2X7 receptor (P2X7R), characterized by a dual response to extracellular ATP [102]. 
Interestingly, the ablation of P2X7R in high-fat diet fed mice reduced the accumulation of AGEs from both glycation 
and lipoxidation reactions, and the activation of AGE-RAGE signaling, with parallel downregulation of NLRP3 
activation and all the inflammasome components expression. The potential of the targeting of P2X7R–NLRP3 axis in 
renal disease of type 2 diabetes and metabolic disorders was also confirmed by analysis on human kidney biopsies 
showing increased expression of P2X7R and NLRP3 in diabetic patients compared to non-diabetic [103]. 
In addition, high glucose levels in cultured podocytes, as well as in streptozotocin-diabetic mice, induced 
accumulation of TXNIP, which played a crucial role in NLRP3 inflammasome activation promoting podocyte and 
glomerular inflammatory injury [101]. Indeed, the inhibition of TXNIP by continuous delivering of TXNIP DNAzyme 
in (mRen-2)27 transgenic rats rendered diabetic by streptozotocin injection, a model of progressive diabetic 
nephropathy, improved oxidative stress, reduced NLRP3 expression, and ameliorated fibrosis within the tubulo-
interstitium [104]. 
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5. THERAPEUTIC INTERVENTIONS TARGETING NLRP3 ACTIVATION IN METAFLAMMATION. 
Several therapeutic approaches have been undertaken in the attempt to both deepen the comprehension of 
NLRP3 involvement in metaflammation and evaluate whether the targeting of NLRP3 in metabolic diseases might be a 
promising strategy of intervention. 
In regards to the NLRP3 activity in the heart, in a recent study Marchetti et al [105] demonstrated an increased 
caspase-1 activity and cell death  in HL-1 cardiomyocytes treated with lipopolysaccharide (NLRP3 priming) and ATP 
(NLRP3 trigger). The increased NLRP3 activity was abolished by 16673-34-0, a new synthesized inhibitor of the 
NLRP3 inflammasome. Moreover, pre-treatment with this inhibitor in a model of acute I/R, a model similar to that of 
Sandanger et al. [68], blunted the activity of caspase-1 and reduced cardiac infarct size. This is in line with a previous 
study of the same group [62] in which the authors showed that the inhibition of the inflammasome by small-interfering 
RNA prevents NLRP3 activation and cardiac cell death, resulting in an improvement of cardiac remodeling. In such a 
study, they suggested that inflammasome activation within cardiomyocytes promotes caspase-1-dependent 
cardiomyocyte death, termed ‘pyroptosis’. 
We have recently confirmed w that the inhibition of NLRP3 activation by acute administration of a novel small 
electrophilic molecule limits the extension of infarct size [106]. In addition, Toldo et al [107] found that only if given 
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within 1h of reperfusion the NLRP3 inflammasome inhibitor, 16673-34-0 [108], limits the secondary inflammatory and 
infarct size injury that usually follow myocardial I/R. Yet, Jong et al. [109] showed no differences in cardiac damage 
between NLRP3(-/-) and wild-type mice in a model of closed-chest myocardial I/R injury. Finally, it has been reported 
that selective inhibition of the NLRP3-inflammasome reduces infarct size and preserves cardiac function also in a large 
animal MI model. Indeed, a 7 days treatment with the NLRP3-inflammasome inhibitor MCC950 significantly reduced 
infarct size and preserved left ventricular ejection fraction in landrace pigs subjected to 75 min transluminal balloon 
occlusion. Moreover, MCC950 treatment reduced myocardial neutrophil influx and IL-1β levels. These results further 
confirm the therapeutic potential of NLRP3-inflammasome inhibition in acute MI patients [110].  
As said above, a number of studies have reported that regulating NLRP3 inflammasome activation with small 
molecule inhibitors is a potential therapeutic strategy to treat or prevent the pathological outcomes of NAFLD 
[30,31,111]. As above mentioned, the activation of NLRP3 in the liver is strictly correlated to the intrahepatic 
accumulation of lipids and thus the inhibition of TNXIP by quercetin and allopurinol leads to the concomitant 
downregulation of SREBP and NLRP3 activities in the liver of streptozotocin-induced diabetic rats [85]. In a very 
recent work, the potential prevention of NAFLD in the liver of high fat fed mice by sulforaphane, an organosulfur 
compound that exhibits potent anti-inflammatory activity and attenuates diet-induced adiposity and hepatosteatosis, has 
been investigated [112]. The results demonstrate that sulforaphane suppresses NLRP3 inflammasome activation in 
hepatocytes preventing hepatic steatosis. Moreover, since the mitochondrial dysfunction is the preceding event 
occurring with saturated fat-induced activation of the NLRP3 inflammasome [37], the same study showed that 
sulforaphane stimulates the autophagic process that recover the mitochondrial dysfunction induced by palmitic acid in 
cultured hepatocytes, thereby downregulating fat-induced activation of the NLRP3 inflammasome through AMPK-
autophagy signaling [112]. 
An interesting natural compound extensively investigated for its beneficial effects mediated by antioxidant and 
anti-inflammatory properties is resveratrol. Resveratrol is a polyphenol found in grape, mulberry and red wine, that has 
been shown to exert cardio-protective and anti-cancer effects [113,114]. Results from in vitro and animal experimental 
models, confirmed by a human clinical trial in diabetic subjects, demonstrated the ability of resveratrol to improve 
insulin resistance and diabetes [115]. In a recent work, four weeks of resveratrol administration improved glycemic 
control and hepatic steatosis in a diet-induced obesity rodent model (10 weeks of 45% high-fat diet) by inhibiting the 
activation of NLRP3 inflammasome and hepatic metaflammation. The activation of AMPK through increase in Sirt-1 
and Sirt-6, and the increased production of the anti-inflammatory cytokine adiponectin, are suggested as the underlying 
mechanisms for the beneficial effects of resveratrol on NLRP3 inflammatory signaling [116].  
In addition to resveratrol, other polyphenols can provide modulation of innate immune response in obesity-
associated NAFLD, as reported by Zou and colleagues [117] who demonstrated the beneficial effect of punicalagin, one 
of the major ellagitannins found in promegranate, on inflammatory markers in the liver of high fat diet-fed rats. In 
particular, punicalagin has been reported to selectively inhibit ATP-induced IL-1β release, but not its processing, in 
NLRP3activated macrophages [118]. Moreover, Tang et al. [119] demonstrated that 4-weeks administration of ellagic 
acid ameliorated monocrotaline-induced pulmonary artery hypertension in rats by inhibiting NLRP3 inflammasome 
signal pathway in lungs. 
Another approach aimed to prevent NLRP3 activation in diet-induced hepatosteatosis is the administration of a 
peroxisome proliferator-activated receptor (PPAR)-δ activator, as shown in a study from Lee and colleagues [120]. In 
this study, the PPAR-δ agonist GW501516 was able to reduce hepatic steatosis, inflammation, and oxidative stress in 
mice fed a high fat diet, although without affecting insulin resistance and hyperlipidemia. In particular, GW501516 
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treatment increased both in vivo and in vitro the phosphorylation of AMPK, which is known to have an anti-
inflammatory effect and suppress ROS production. Since in immune cells the AMPK-ROS signaling pathway is 
associated with the activation of the NLRP3 inflammasome, the activation of AMPK may be the potential mechanism 
underlying the inhibitory effect of PPAR- δ agonist on NLRP3 [120]. 
The fact that PPAR-δ plays important roles in the regulation of metabolism and attenuation of NLRP3 
inflammatory pathway, has been firstly evidenced in a mouse model of high-fructose corn syrup-induced 
dysmetabolism, where the administration of the PPAR-δ agonist GW0742 ameliorated systemic glucose and lipid 
metabolism, as well as hepatic insulin resistance, by preventing NLRP3 activation in the kidney [30].  
Finally, very recent findings have highlighted new therapeutic potential of the sodium glucose cotransporter 
(SGLT)-2 inhibitor empagliflozin, currently employed as oral hypoglycemic drug for the treatment of type 2 diabetes. 
Indeed, empagliflozin attenuated the metabolic abnormalities induced by chronic exposure to a high-fat high-sucrose 
diet decreasing the hepatic and renal tissue injury associated with obesity and insulin resistance, but interestingly, 
empagliflozin reduced in a dose-dependent manner the diet-induced activation of NLRP3 inflammasome pathway in 
both liver and kidney [121]. 
In addition, as above seen for the liver, also in kidney the same mechanism related to TXNIP inhibition is 
involved in the positive effects exerted by several natural compounds provided with antioxidant properties on renal 
function. In fact, compounds such as piperine, an active alkaloidal phenolic component of black pepper, cepharanthine, 
a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata, pterostilbene, a natural dimethylether derivative 
of resveratrol, or the Simiao pill, a famous traditional Chinese medicine formula, preserved renal function in animal 
models of streptozotocin- and diet-induced diabetes and MS by reducing NLRP3 activation through prevention of ROS-
induced TXNIP production [122-124]. 
Among the numerous promising strategies for the preservation of kidney function in MS and diabetes through 
NLRP3 inhibition, we have previously cited the positive results of PPARδ agonists and SGLT-2 inhibitor in both 
hepatic and renal tissue [30,121]. It can be mentioned also a study on a dipeptidyl peptidase (DPP) 4 inhibitor, 
saxagliptin which was found to attenuated diabetes-induced activation of the inflammasome and progression of diabetic 
nephropathy in two models of type 1 (Akita mice) and type 2 (BTBR mice) diabetes. In particular, the effects of 
saxagliptin in the Akita mice were independent of glucose lowering [125]. 
A novel and promising treatment option for MS-related disease is the use of selective inhibitors of the NLRP3 
inflammasome. To date, no specific and selective compounds are available for the inhibition of inflammasome 
activation in MS. However, a very recent study highlighted that the pharmacological inhibition of the inflammasome by 
the use of the selective NLRP3 inhibitor BAY 11-7082, given to mice only for the last 7 wks of the 12-wks of high-fat 
high-sucrose diet, reversed the deleterious effects of diet exposure preventing the development of insulin resistance and 
attenuating in both liver and kidney markers of fibrosis and inflammation, thus preserving organ dysfunction [30]. 
 
6. CONCLUSIONS 
Here we provide evidences that NLPR3 inflammasome activation, in which ROS formation may play a pivotal 
role, is involved in several pathological conditions related with MS. Therefore, it is likely that oxidative stress and 
NLRP3 inflammasome activation may be common pathogenic denominators linking metaflammation to MS. NLRP3 
inflammasome activation is also involved in the exacerbation of myocardial I/R injury and prophylactic or post-
ischemic treatments with selective NLRP3 inhibitor limit I/R damage. These findings convincingly support its role as 
cross-talk mechanism in cardio-metabolic diseases. The tight relationship between lipid metabolism unbalance and 
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NLRP3 inflammasome activation in the liver seems to be the triggering factor for the progression of NAFLD to NASH 
in MS. Indeed, many strategies aimed at the modulation of lipid synthesis also limit the NLRP3 activation, and 
viceversa, when acting a direct inhibition of NLRP3 the lipid metabolism is improved as consequence. 
Besides the dysregulated lipid metabolism, the hyperglycemia, often present in MS, has an important role in the 
inflammatory response and specifically in NLRP3 activation leading to renal dysfunction. In particular, hyperglycemia 
in the kidney is strictly related to oxidative stress and AGEs accumulation, which, as extensively demonstrated, play a 
crucial role in NLRP3 activation and chronic inflammation.  Any strategy targeting the reduction of oxidative stress or 
the inhibition of AGEs accumulation or AGE-RAGE signaling exert a positive effect on kidney function through the 
modulation of NLRP3 activation. 
In summary, in the present review recently discovered characteristics of NLRP3 activity and regulation are 
highlighted as far as they might lead to selective intervention by specific drugs. Indeed, pharmacological modulation of 
NLRP3 inflammasome has the potential to exert beneficial effects in the control of metabolic dysregulation and its 
cardiovascular, hepatic and renal complications. Drugs targeting NLRP3 may thus represent unique tools in therapeutic 
armamentarium against MS-related diseases. They could be protagonists in the strategies aimed to address the burden of 
cardiovascular, kidney and liver-related morbidity and mortality, due to the co-presence of MS, obesity and insulin 
resistance. Clearly, there is a stringent need to dedicate considerable effort in understanding such pathological 
conditions and therapeutic potential if we are to “bridge the gap”. A hope of progress comes from the development of 
new promising technologies, including the so-called omic sciences, the investigations of ROS-dependent pathways, and 
the studies on the role of stem and progenitor cells. In this perspective, animal studies on models of risk factors for 
CVD and comorbidities, such as those correlated to MS, are essential for adequate successive clinical translation. Basic 
and translational studies may help to clarify how effective is a therapeutic strategy which include NLRP3 inhibitors in 
order to potentially prevent and cure metaflammation-mediated diseases. 
 
LIST OF ABBREVIATIONS 
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